Alpine Immune Sciences Executives
Alpine Immune employs about 142 people. The company is managed by 10 executives with a total tenure of roughly 14 years, averaging almost 1.0 years of service per executive, having 14.2 employees per reported executive. Analysis of Alpine Immune's management performance can provide insight into the firm performance.
| Paul Rickey President CFO, Senior Vice President Secretary |
Alpine |
Alpine Immune Management Team Effectiveness
The company has return on total asset (ROA) of (0.101) % which means that it has lost $0.101 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1467) %, meaning that it created substantial loss on money invested by shareholders. Alpine Immune's management efficiency ratios could be used to measure how well Alpine Immune manages its routine affairs as well as how well it operates its assets and liabilities.Alpine Immune Workforce Comparison
Alpine Immune Sciences is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 1,768. Alpine Immune holds roughly 142 in number of employees claiming about 8% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.65) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.23) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.23. Alpine Immune Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alpine Immune insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alpine Immune's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Alpine Immune insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Remy Durand over six months ago Disposition of 78000 shares by Remy Durand of Alpine Immune at 18.33 subject to Rule 16b-3 | ||
Topper James N over six months ago Disposition of 1200000 shares by Topper James N of Alpine Immune at 0.001 subject to Rule 16b-3 | ||
Mitchell Gold over six months ago Disposition of 74441 shares by Mitchell Gold of Alpine Immune at 12.74 subject to Rule 16b-3 | ||
Fuhs Ulrich Martin over six months ago Disposition of 75000 shares by Fuhs Ulrich Martin of Alpine Immune at 12.07 subject to Rule 16b-3 | ||
Peter Thompson over a year ago Acquisition by Peter Thompson of 17500 shares of Alpine Immune subject to Rule 16b-3 | ||
Peter Thompson over a year ago Sale by Peter Thompson of 162576 shares of Alpine Immune | ||
James Topper over a year ago Exercise of in-the-money or at-the-money derivative position by James Topper of 145251 shares of Alpine Immune | ||
Rickey James Paul over a year ago Exercise or conversion by Rickey James Paul of 700 shares of Alpine Immune subject to Rule 16b-3 |
Alpine Immune Notable Stakeholders
An Alpine Immune stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Alpine Immune often face trade-offs trying to please all of them. Alpine Immune's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Alpine Immune's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Mitchell MD | Executive CEO | Profile | |
| Paul Rickey | CFO, Senior Vice President Secretary | Profile | |
| Stanford MD | President Development | Profile | |
| Temre Johnson | Head Communications | Profile | |
| Remy Durand | Chief Officer | Profile | |
| Andrew MD | Chief Officer | Profile | |
| Wayne Gombotz | Chief Officer | Profile | |
| Pamela Holland | VP Research | Profile | |
| Wolfgang MD | Chief Officer | Profile | |
| Christina Yi | Chief Officer | Profile |
Alpine Immune Workforce Analysis
Traditionally, organizations such as Alpine Immune use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Alpine Immune within its industry.Alpine Immune Manpower Efficiency
Return on Alpine Immune Manpower
| Revenue Per Employee | 414.6K | |
| Revenue Per Executive | 5.9M | |
| Net Loss Per Employee | 226.6K | |
| Net Loss Per Executive | 3.2M | |
| Working Capital Per Employee | 2M | |
| Working Capital Per Executive | 28.8M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Alpine Stock
If you are still planning to invest in Alpine Immune Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alpine Immune's history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |